Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions
Advanced Biliary Tract Cancer
Interventions
DRUG

Lenvatinib Pill,Paclitaxel

Regimen Every 28 days as one cycle.Lenvatinib 16 or 12 mg/day orally (depends on the result of safety run-in phase), on day 1-28; Paclitaxel 80 mg/m2 in 250-500 mL of normal saline, intravenously over 2 hours on day 1, 8, 15.

Trial Locations (8)

Unknown

Chang Gung Memorial Hospital, Kaohsiung City

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

China Medical University Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

MacKay Memorial Hospital, Taipei

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei

Chang Gung Memorial Hospital, Taoyuan District

All Listed Sponsors
collaborator

National Cheng-Kung University Hospital

OTHER

collaborator

National Taiwan University Hospital

OTHER

collaborator

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

China Medical University, Taiwan

OTHER

collaborator

Mackay Memorial Hospital

OTHER

lead

National Health Research Institutes, Taiwan

OTHER